Summary:
Recently, Kactus Biosystems (Shanghai) Co., Ltd. (abbreviation: Kactus ) and Zhejiang Hengkang Pharmaceutical Co., Ltd. ( abbreviation : Hengkang Pharm) announced a deeper strategic partnership . In-depth exchanges were held, and the depth of cooperation in the field of mRNA segmentation was actively explored. Through this strategic cooperation, the two parties will further promote more comprehensive and in-depth cooperation in mRNA synthesis raw materials, give full play to the advantages of both parties, and effectively combine the chemical synthesis industry platform with Kactus's unique protein research and development platform SAMS, to provide mRNA synthesis raw material for the downstream clients of the chain more efficiently, conveniently and stably, and help empower the rapid and healthy development of the mRNA vaccine industry.
// Mr. Edmund Wang, the founder and CEO of Kactus, said:
Hengkang Pharm has professional capabilities in chemical nucleotide R&D and large-scale production for many years, as well as its experience in GMP system, drug regulation and documentation filing, registration in the international market, have played a good strategic role in the business expansion of Kactus in the nucleic acid drug industry. The leading GMP protease products of Kactus are matched with the rigorously tested high-quality nucleotide and cap analogs of Hengkang Pharm to create a one-stop core raw material product, providing high-quality and convenient solutions for mRNA drug/vaccine customers .
// Ms. Yao Hong, CEO of Hengkang Pharm, said:
In the past year, the cooperation between Hengkang Pharm and Kactus have achieved initial results. With the cooperation of both parties, it can better serve clients in the mRNA drug/vaccine industry. The cooperation between the two parties has fully proved the contribution of complementary advantages to industrial development, greatly reduced the supply chain costs of global clients, and actively catalyzed and accelerated the comprehensive substitution of localized raw materials in the mRNA drug/vaccine industry. In the future, the two parties will take advantage of their respective industrial advantages, synergistically leverage the advantages of the chemical synthesis industry platform of Hengkang Pharm and the protein R&D platform of Kactus, and jointly deploy a high-fusion platform in the field of mRNA industry, so as to serve the downstream CDMO, CMO, vaccine preparations, etc. of the mRNA industry. To create more advantageous services and provide comprehensive products for the mRNA industry.
About |
Founded in early 2018, Kactus is a GMP enyzme and recommbinant protein company that focuses on the upstream field of biopharmaceuticals and is driven by independent innovation. Relying on the unique protein research and development platform SAMS, Kaijia Biotech entered the antibody drug market from the field of difficult transmembrane proteins to solve unmet market needs.
In the field of gene therapy, Kactus is the first company in China to provide GMP-grade Cas9 enzymes that can meet the clinical needs of gene editing. At the same time, Kactus provides GMP-grade all-purpose nucleases for AAV and vaccine industries, and cell therapy Cytokines and raw enzymes for mRNA vaccine production. Among them, Cas9 enzyme , totipotent nuclease , BsaI , and T7 RNA Polymerase have all completed DMF filing. The GMP products of Kactus strictly follow the Pharmacopoeia for detection method development and verification, equipped with MES digital production management system, the products have good batch-to-batch stability and consistency, meet the declaration requirements, and can provide various declaration documents.
Kactus obtained the national high-tech enterprise qualification in 2019, and successfully passed the ISO13485:2016 medical device quality management system certification on January 20, 2022. The company has a 5,000-square-meter R&D and production center and a technical team of nearly 250 people in Caohejing Development Zone, Pujiang Town, Shanghai. At the same time, it has established a GMP-grade protease industrialization base of tens of thousands of square meters in Shanghai Lingang New Area.
About | Hengkang Pharm
Zhejiang Hengkang Pharmaceutical Co., Ltd. is a pharmaceutical company covering front-end research and development of drugs, large-scale production and global marketing. The company has been committed to the R&D, production and sales of high-end active drugs, and is committed to providing customers with high-quality pharmaceutical products and professional services; the company has workshops and facilities that meet global standards cGMP standards, professional GMP and EHS management systems and marketing teams, The business covers China, Europe, Japan, South Korea, CIS region, the Middle East and other mainstream pharmaceutical markets and emerging pharmaceutical markets; after years of hard work by the team, it has established long-term and stable cooperative relations with nearly 70 overseas countries and hundreds of domestic companies. The company has obtained domestic and foreign registration certificates for multiple products, and has passed on-site inspections by official agencies such as China's NMPA, EU's EDQM, Japan's PMDA, and South Korea's KFDA. The company has a number of core patents for self-developed products, and has successively won honors such as national high-tech enterprises and provincial research institutes.
The nucleic acid business unit of the group focuses on key raw materials for mRNA drugs/vaccine and oligonucleotide drugs, nucleotides, modified nucleotides, cap analogs, cationic liposomes, phosphoramidite monomers (DNA phosphoramidite monomers, RNA phosphoramidite monomer, etc.), the company's many years of industrialization experience, to build a large production base with advanced GMP system, the design production capacity of 8 billion doses per year, to ensure the stable supply of high-quality raw materials, to solve key problems Cost issues and bottleneck projects will improve the industrial structure; we will go all out to do a good job in supply chain services.
